Kyle Doherty

Kyle Doherty joined MJH Life Sciences in 2021 and is the lead editor for Oncology Fellows. He also produces print content for OncologyLive, as well as news and conference updates for OncLive.com. Email: kdoherty@mjhlifesciences.com

Articles

IMvigor011 Confirms ctDNA Status as Key Predictor of Adjuvant Atezolizumab Efficacy in MIBC

October 24th 2025

Joaquim Bellmunt, MD, PhD, discusses the rationale for and findings from the IMvigor011 trial of ctDNA-guided adjuvant atezolizumab vs placebo in MIBC.

International Medical Graduates Produce Significant Research Contributions During Hematology/Oncology Fellowship

October 24th 2025

Arya Mariam Roy, MD, MBBS, discusses a study of the research productivity of hematology/oncology fellows who are international medical graduates.

Dr Salutari on the Rationale for Evaluating Relacorilant Plus Nab-Paclitaxel in PARP Inhibitor–Treated PROC

October 23rd 2025

Vanda Salutari, MD, discusses the rationale for examining relacorilant plus nab-paclitaxel in PARP inhibitor–treated platinum-resistant ovarian cancer.

Dr Yuan on Dual-Pathway Targeted Strategies in ER+/HER2+ Breast Cancer

October 23rd 2025

Yuan Yuan, MD, PhD, discusses the importance of optimizing dual-pathway targeting in ER-positive, HER2-positive metastatic disease.

Dr Wang on a Retrospective Study of CNS Bridging Radiotherapy Prior to CAR T in B-Cell Lymphoma

October 23rd 2025

Pule Wang, MD, discusses the design of a retrospective study of CNS bridging radiation therapy prior to CAR T in B-cell lymphomas.

Shorter Duration of Chemotherapy Associated With Improved PROs in Advanced Urothelial Cancer

October 23rd 2025

Three cycles of platinum-based chemotherapy yielded superior PROs vs 6 cycles in advanced urothelial cancer.

Dr Tarantino on De-Escalated THP With/Without Carboplatin in HER2+ Breast Cancer

October 23rd 2025

Paolo Tarantino, MD, PhD, discusses key efficacy data with de-escalated THP with/without carboplatin in HER2-positive breast cancer.

Dr Visco on the Efficacy and Safety of Venetoclax Plus RBAC in High-Risk MCL

October 23rd 2025

Carlo Visco, MD, discussed patient characteristics, efficacy data, and safety findings from the FIL_V-RBAC study of venetoclax plus RBAC in MCL.

Dr Randall on the Potential Role of Ultrasound in Soft Tissue Sarcoma Surveillance

October 23rd 2025

R. Lor Randall, MD, FACS, summarizes the current status of and future directions for imaging protocols for post-surgical extremity STS surveillance.

Dr Tagawa on the Rationale for Evaluating Lutetium Lu 177 Vipivotide Tetraxetan Plus ARPI and ADT in PSMA+ mHSPC

October 22nd 2025

Scott T. Tagawa, MD, MS, FACP, FASCO, discusses the background of a phase 3 trial of lutetium Lu 177 vipivotide tetraxetan plus ARPI and ADT in mHSPC.

Real-World Studies Reinforce Axi-Cel and Liso-Cel as Effective LBCL Treatments

October 22nd 2025

Taylor Brooks, MD, discusses ways that the availability of CAR T-cell therapies has augmented the relapsed/refractory LBCL treatment paradigm.

Dr Hassel on the Rationale for Combining IO102-IO103 with Pembrolizumab in Treatment-Naive Advanced Melanoma

October 22nd 2025

Jessica C. Hassel, MD, discusses rationale for combining IO102-IO103 with pembrolizumab in patients with treatment-naive advanced melanoma.

Atezolizumab Plus Bevacizumab Shows Early TTFS Edge Over TACE in HCC

October 22nd 2025

Atezolizumab plus bevacizumab displayed preliminary signs of a TTFS benefit vs TACE in intermediate-stage HCC.

Dr Gupta on Responses With Enfortumab Vedotin/Pembrolizumab in Urothelial Carcinoma

October 22nd 2025

Shilpa Gupta, MD, discusses response and subgroup data with enfortumab vedotin plus pembrolizumab in locally advanced/ metastatic urothelial carcinoma.

CAR2219 CAR T-Cell Therapy Yields Responses and a Manageable Safety Profile in R/R LBCL

October 21st 2025

CAR2219 induced high response rates in relapsed/refractory LBCL, and the role of post-infusion maintenance therapy is worthy of further study.

HLX43 Nets FDA Orphan Drug Designation in Thymic Epithelial Tumors

October 21st 2025

The FDA granted orphan drug designation to HLX43 for thymic epithelial tumors

Long-Term DeFi Data Confirm Durable Efficacy and Consistent Safety of Nirogacestat in Desmoid Tumors

October 21st 2025

Final DeFi trial results show sustained responses, improved PROs, and a stable safety profile with long-term nirogacestat in desmoid tumors.

Dr Gerds on Notable Ongoing Clinical Trials in Myelofibrosis

October 21st 2025

Aaron T. Gerds, MD, MS, discusses clinical trials to watch in the evolving myelofibrosis research paradigm.

Dr Mouhieddine on Clinical Implications of Ferritin and ALC as Biomarkers in Myeloma

October 21st 2025

Tarek Mouhieddine, MD, discusses data from a study of ferritin and ALC as biomarkers of response to bispecific antibodies in relapsed/refractory myeloma.

ctDNA-Guided Adjuvant Atezolizumab Boosts DFS, OS in Muscle-Invasive Bladder Cancer

October 20th 2025

Adjuvant atezolizumab improved DFS and OS in patients with muscle-invasive bladder cancer who tested positive for ctDNA after radical cystectomy.